Modulation of prion expression
View Patent ↗Disclosed herein are compounds and methods for decreasing PrP and preventing, ameliorating, or treating a prion disease or conformational neurodegenerative disorder, in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to PrP include Creutzfeldt-Jakob disease (CJD); variant Creutzfeldt-Jakob Disease (vCJD); Gerstmann-Straussler-Scheinker syndrome; fatal familial insomnia; kuru; Bovine Spongiform Encephalopathy (BSE), e.g. “mad cow disease”; Chronic Wasting Disease (CWD); scrapie; transmissible mink encephalopathy; feline spongiform encephalopathy; ungulate spongiform encephalopathy; Alzheimer's disease; Parkinson's disease; Huntington's disease; and Amyotrophic Lateral Sclerosis (ALS).
1. A modified antisense oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the modified antisense oligonucleotide is a gapmer and is fully complementary to an equal number of consecutive nucleobases selected from 469 to 2629 of the human PrP nucleic acid of SEQ ID NO:1.
2. The modified antisense oligonucleotide of claim 1 , wherein the modified oligonucleotide is a single-stranded oligonucleotide.
3. The modified antisense oligonucleotide of claim 2 , wherein at least one internucleoside linkage is a modified internucleoside linkage.
4. The modified antisense oligonucleotide of claim 3 , wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.
5. The modified antisense oligonucleotide of claim 4 , wherein at least one nucleoside comprises a modified sugar.
6. The modified antisense oligonucleotide of claim 5 , wherein at least one modified sugar is a bicyclic sugar.
7. The modified antisense oligonucleotide of claim 5 , wherein at least one modified sugar is a 2 ′-O-methoxyethyl.
8. The modified antisense oligonucleotide of claim 2 , wherein at least one nucleoside comprises a modified nucleobase.
9. The modified antisense oligonucleotide of claim 8 , wherein the modified nueleobase is a 5-methylcytosine.
10. A method of inhibiting expression of PrP an animal, comprising administering to the animal the modified antisense oligonucleotide of claim 1 .
11. A modified antisense oligonucleotide consisting of 12 to 30 linked nucleosides, wherein the modified antisense oligonucleotide is fully complementary to an equal number of consecutive nucleobases selected from 469 to 2629 of the human PrP nucleic acid of SEQ ID NO: 1.
12. The modified antisense oligonucleotide of claim 11 , wherein the modified oligonucleotide is a single-stranded oligonucleotide.
13. The modified antisense oligonucleotide of claim 12 , wherein at least one internucleoside linkage is a modified internucleoside linkage.
14. The modified antisense oligonucleotide of claim 13 , wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.
15. The modified antisense oligonucleotide of claim 14 , wherein at least one nucleoside comprises a modified sugar.
16. The modified antisense oligonucleotide of claim 15 , wherein at least one modified sugar is a bicyclic sugar.
17. The modified antisense oligonucleotide of claim 15 , wherein at least one modified sugar is a 2 ′-O-methoxyethyl.
18. The modified antisense oligonucleotide of claim 12 , wherein at least one nucleoside comprises a modified nucleobase.
19. The modified antisense oligonucleotide of claim 18 , wherein the modified nucleohase is a 5-methylcytosine.
20. The modified antisense oligonucleotide of claim 6 , wherein the bicyclic sugar is a (6′S)-6′methyl BNA.
21. The modified antisense oligonucleotide of claim 16 , wherein the bicyclic sugar is a (6′S)-6′methyl BNA.
22. A method of inhibiting expression of PrP in an animal, comprising administering to the animal the modified antisense oligonucleotide of claim 11 .
23. The modified antisense oligonucleotide of claim 1 , wherein said modified antisense oligonucleotide consists of 15 to 30, 18 to 24, or 19 to 22 linked nucleosides.
24. The modified antisense oligonucleotide of claim 1 , wherein said modified antisense oligonucleotide consists of 20 linked nucleosides.
25. The modified antisense oligonucleotide of claim 11 , wherein said modified antisense oligonucleotide consists of 15 to 30, 18 to 24, or 19 to 22 linked nucleosides.
26. The modified antisense oligonucleotide of claim 11 , wherein said modified antisense oligonucleotide consists of 20 linked nucleosides.
27. The modified antisense oligonucleotide of claim 1 , wherein the gap segment of the oligonucleotide consists of 2-deoxynucleotides and wherein each wing segment of the oligonucleotide consists of 2-O-methoxyethyl-modified nucleotides.
28. The method of claim 10 , wherein the gap segment of the oligonucleotide consists of 2-deoxynucleotides and wherein each wing segment of the oligonucleotide consists of 2′-O-methoxyethyl-modified nucleotides.
29. The modified antisense oligonucleotide of claim 23 , wherein the gap segment of the oligonucleotide consists of 2′-deoxynucleotides and wherein each wing segment of the oligonucleotide consists of 2′-O-methoxyethyl-modified nucleotides.
30. The modified antisense oligonucleotide of claim 24 , wherein the gap segment of the oligonucleotide consists of 2′-deoxynucleotides and wherein each wing segment of the oligonucleotide consists of 2′-O-methoxyethyl-modified nucleotides.